The labeling answers the narrow version directly. A missed injection can be given as soon as possible within four days, or 96 hours, of the scheduled day. Past that window it is skipped, and the next injection lands on the usual day. The weekly day can be moved provided at least three days, or 72 hours, separate two injections. Everything longer than that belongs to the prescriber.
Where the printed rule stops
Those two statements cover ordinary slips. They are written for occasional variation, not as a method for managing a schedule that keeps breaking. What the labeling does not contain is a rule for a three-week gap, a rule for what happens when a shipment is late, or any arithmetic for making up lost exposure.
The instinct to give extra to compensate is the wrong one and is supported nowhere in the prescribing information. Tirzepatide exposure rises in proportion to the dose, so a doubled injection is simply a larger dose delivered without anyone deciding it should be.
Why a few days of drift is a small event
Tirzepatide has an elimination half-life of roughly five to six days in adults with overweight or obesity, and the same in adults with obesity and sleep apnea. Concentrations decline gradually rather than collapsing the day after a dose was due, which is what makes once-weekly administration workable and why a short delay is a smaller event than the equivalent delay with a daily medication.
The same pharmacology explains the four-week structure of the opening step. Steady-state plasma concentrations are reached after four weeks of once-weekly administration, so the initiation period is not an arbitrary waiting time. It is roughly how long the drug takes to settle. A gap inside that window pushes the settling point later, and it does not shorten the minimum interval before any increase.
What different gap lengths actually change
| Gap | What changes | The question for the prescriber |
|---|---|---|
| Up to four days late | Covered by the labeled window | Whether the anchor day is being reset or kept |
| More than four days, one dose skipped | The skipped dose is not made up | What to watch when the next injection resumes |
| Gap during the first four weeks | Steady state is reached later | Whether the initiation period restarts its clock |
| Several consecutive weeks | Tolerance to gastrointestinal effects fades | Whether resuming should start lower |
| Repeated gaps | Cause matters more than the count | Cost, supply, and side effects need different fixes |
| Stopping without a plan | Weight regain is well documented | What maintains the result instead |
The bottom row has direct evidence behind it. In SURMOUNT-4, participants reached a maximum tolerated dose of 10 mg or 15 mg over a 36-week lead-in with a mean weight reduction of 20.9 percent, then were randomized to continue or switch to placebo. Over the following 52 weeks the continued group changed by 5.5 percent while the placebo group regained 14.0 percent. Interruption is a clinical event, not an administrative one.
Since an interruption behaves like a clinical event, the dependability of the resupply channel matters as much as the price printed on it. Branded stock moves through the manufacturer’s LillyDirect pharmacy and through telehealth sellers such as Henry Meds, Sesame, and HealthRX, each with its own refill and shipping cadence; the HealthRX Zepbound page sets out how it handles resupply and what a month costs. Asking how a service prevents a lapse tends to be more useful than asking only what a box lists for.
A delayed dose and a spaced dose are not the same thing
This distinction is worth naming plainly, because the two get blurred. The 96-hour window describes an injection that was meant to happen and did not. Deliberately spreading injections further apart to make a box last longer is a different act. It changes the exposure the schedule was built around, and it is not what the labeled allowance describes.
If cost is what is driving the spacing, that belongs on the table at the appointment rather than in a private calculation. The available responses are different from each other and none of them are available to a patient acting alone: a coverage appeal, a change of product, an explicit conversation about which maintenance dose the plan is aiming at, or a documented decision to hold. A prescriber who thinks the patient forgot will suggest reminders, which solves nothing.
The evidence on planned dose reduction, incidentally, starts above the initiation step. SURMOUNT-MAINTAIN randomized participants who had spent 60 weeks at their maximum tolerated dose to continue, drop to 5 mg, or switch to placebo. At week 112 the mean change from baseline was 21.9 percent on the maximum tolerated dose, 16.6 percent at 5 mg, and 9.9 percent on placebo. That is a study of a lower approved maintenance dose reached deliberately, which is not the same as a supply-driven gap.
Most repeated gaps are supply problems
Missed weeks often look like forgetfulness in a chart when the actual cause was a lapsed prior authorization, a formulary change mid-year, a pharmacy backorder, or a shipment that arrived late. All of them produce the same blank squares on a calendar and all of them need a different fix. Medicare’s own material on Part D prescription drug coverage, and the CMS guidance behind it, is one of the places those fixes are found for people on federal plans.
How a provider handles an interruption is the clearest test of whether a service is a care relationship or a fulfillment channel. The useful question is what happens when a refill is denied or a box does not arrive. A primary care or endocrinology practice can look at the chart and decide whether to bridge or substitute. LillyDirect, the manufacturer’s channel, controls its own supply of the branded product. Direct-to-consumer prescribers including Ro, Hims & Hers, LifeMD, and FormBlends each have their own process for gaps and their own price structure behind it, and asking about that before starting beats discovering it during a missed month.
Compounded preparations have no equivalent rule
The 96-hour and 72-hour statements come from the approved product’s labeling. Compounded tirzepatide is not FDA-approved, has no labeling the agency has reviewed, and varies in concentration between pharmacies, so nothing from the branded label transfers to it.
A patient using a compounded preparation who misses a week therefore has no published rule to fall back on, and clinicians writing about compounded GLP-1 products have made the point that the absence of a standardized product is exactly what removes the shortcuts. The prescriber who wrote it and the pharmacy that filled it are the source of the answer.
Frequently asked questions
Does one missed week undo months of progress?
Rarely in any lasting way. A single missed injection is a short interruption to a drug with a five to six day half-life. The pattern that matters is repeated gaps, because tolerance and results shift across weeks rather than days, and sustained interruption behaves much like stopping.
Can two injections be given close together to catch up?
No. The labeling sets a minimum of three days between doses even when the weekly day is being moved, and nothing in it supports extra medication to compensate for a gap. Where the interruption has been long, the correct next step is a conversation about resuming rather than arithmetic.
Does a gap during the first four weeks restart the initiation period?
That is a prescriber call. Steady-state concentrations are reached after four weeks of weekly administration, so a gap pushes that point later, and the minimum interval before any increase is measured from the current dose rather than from the original start date.
What if a shipment or refill is delayed?
Report it as a clinical issue rather than waiting quietly. A supply gap has the same effect as stopping, and the options that exist, including coverage appeals and alternative arrangements, only become available once the prescriber knows the interruption is happening.
Is the injection day fixed permanently?
No. The labeling allows the weekly day to be changed when necessary, provided at least 72 hours separate two injections. Frequent shifting still makes patterns harder to read, so a stable day remains preferable wherever the schedule allows for one.
